Elevance Health beats Q2 outlook, raises full-year EPS guidance to at least $27.00

What happened

Elevance Health reported second-quarter 2026 results that exceeded expectations, driven by disciplined execution and improved operating performance across its diversified portfolio. The company raised its full-year 2026 adjusted EPS guidance to at least $27.00, up from the prior at least $25.50, signaling stronger underlying earnings momentum. Management is accelerating targeted investments in medical cost management, member experience, and provider connectivity, which could further support margins. The guidance raise suggests that the elevated benefit expense ratio trends may be stabilizing, and any lingering regulatory overhang from the CMS sanction appears to be easing. As a result, the investment case for ELV shifts from a wait-and-see approach to a more constructive stance, albeit with continued attention on medical cost trends.

Implication

With the guidance upgrade and likely resolution of the CMS sanction, the thesis has improved. Investors should consider initiating positions, but monitor future medical cost trends and ensure the BER remains within guided bounds. The price target could move toward the base case of $350 or higher if the operational improvements persist.

Thesis delta

The prior thesis was centered on uncertainty around CMS sanctions and medical cost escalation, which justified a WAIT rating. The Q2 beat and guidance raise to at least $27.00 indicate that both risks are abating: CMS sanctions have likely been lifted or mitigated, and cost trends are being managed effectively. This shifts the investment thesis from cautious wait to a more favorable outlook, supporting a potential re-rate toward the base-case implied value of $350.